Form 4 for INBX Inhibrx Biosciences, Inc.
Accepted 2024-05-30 00:00:00 ET · period of report 2024-05-29 · accession 0000950142-24-001491 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2024-05-30 | 2024-05-29 | INBX | FORSYTH DOUGLAS | Dir | A - Grant | — | +149.6K | 149.6K | New | — |
| D | 2024-05-30 | 2024-05-30 | INBX | FORSYTH DOUGLAS | Dir | A - Grant | $0.00 | +30.0K | 30.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-29 | A | A | 149,564 | — | 149,564 | I By the Forsyth Family Trust Dated July 20, 2001 | — | — | (F1) The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. (F2) The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001. |
| 2 | Derivative | Stock Option (right to buy) | 2024-05-30 | A | A | 30,000 | $0.00 | 30,000 | D | $15.86 · — to 2034-05-30 | 30,000 Common Stock | (F3) This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi. (F4) This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date. |